Previous 10 | Next 10 |
- Trust 2 Study confirms negative predictive value (NPV) of 99.7% for the foundational gene expression assay - Optional TERT promoter mutation testing does not significantly alter sensitivity, NPV or positive predictive value (PPV) DermTech, Inc. (NASDAQ: DMTK) (DermTech or th...
2024-01-08 10:26:35 ET More on DermTech DermTech, Inc. (DMTK) Q3 2023 Earnings Call Transcript DermTech Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on DermTech Historical earnings data for DermTech Financial information for DermTech ...
- Trust 2 Study demonstrated powerful clinical utility for the DMT as a rule-out test for melanoma - Negative predictive value (NPV) higher than 99% DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomi...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In DermTech To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in DermTech stock or options between March 8, 2021 and November 3, 2022 a...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In DermTech To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in DermTech stock or options between March 8, 2021 and November 3, 2022 a...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In DermTech To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in DermTech stock or options between March 8, 2021 and November 3, 2022 a...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In DermTech To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in DermTech stock or options between March 8, 2021 and November 3, 2022 a...
SAN DIEGO, CA / ACCESSWIRE / December 5, 2023 / The Shareholders Foundation, Inc. announces that a deadline is coming up on December 15, 2023 in the lawsuit that was filed for certain investors in DermTech, Inc. (NASDAQ:DMTK) shares. Investors, who purchased shares in excess of $100,000 DermTec...
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a deadline is coming up on December 15, 2023 in the lawsuit that was filed for certain investors in DermTech, Inc. (NASDAQ: DMTK) shares. Investors, who purchased shares in excess of $100,000 DermTec...
2023-11-02 19:27:06 ET DermTech, Inc. (DMTK) Q3 2023 Earnings Conference Call November 2, 2023, 5:00 pm ET Company Participants Steve Kunszabo - Head, IR Bret Christensen - President & CEO Kevin Sun - CFO Conference Call Participants Thomas Flaten...
News, Short Squeeze, Breakout and More Instantly...
DermTech Inc Company Name:
DMTK Stock Symbol:
NYSE Market:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th i...